Evidence map›Paper›PMID 37900835›Full record

ArticleCase reports in oncology

Keisuke Okubo, Shintaro Narita, Atsushi Koizumi, Yoshiko Takahashi, Ryuichiro Sagehashi, Kanami Mori, Ryuta Sobu, Hiromi Sato, Soki Kashima, Mizuki Kobayashi and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Keisuke OkuboDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Shintaro NaritaDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Atsushi KoizumiDepartment of Urology, Akita Red Cross Hospital, Akita, Japan.
Yoshiko TakahashiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Ryuichiro SagehashiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Kanami MoriDepartment of Urology, Omagari Kousei Medical Center, Akita, Japan.
Ryuta SobuDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Hiromi SatoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Soki KashimaDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Mizuki KobayashiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Ryohei YamamotoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Taketoshi NaraDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Mitsuru SaitoDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Hiroshi NanjoPathology, Akita University Hospital, Akita, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, Akita, Japan.
Akita University · JPAkita Red Cross Hospital · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone metastasis were observed. The patient was referred to our hospital because of biochemical and radiographic progression after four cycles of docetaxel as a first-line therapy for castration-resistant prostate cancer. Transurethral resection of the prostate and hepatic biopsy revealed small-cell carcinoma with positive expression of neuroendocrine markers. The FoundationOne CDx next-generation sequencing test revealed several pathogenic variants, including

Indexed as

BRCA2Neuroendocrine differentiationProstate cancerSmall-cell carcinoma

Identifiers

PMID37900835
PMCPMC10601763
OpenAlexW4385802919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.